KLOW

Typical use cases

Dosing guidelines

Titration

Community protocols often describe a loading phase (e.g., weeks 1-4 once daily) followed by a maintenance phase (weeks 5-8 once daily or tapered to ~5 days/week), then a break. This is reported practice, not a clinical recommendation.

Reconstitution

For a typical 80 mg vial (50 mg GHK-Cu + 10 mg each BPC-157, TB-500, KPV): reported reconstitution is ~3.0 mL bacteriostatic water for ~26.7 mg/mL total (GHK-Cu ~16.7 mg/mL; each other component ~3.33 mg/mL), or 4.0 mL for 20 mg/mL total (GHK-Cu 12.5 mg/mL; others 2.5 mg/mL each). Swirl gently, do not shake.

Injection sites

Subcutaneous injection, typically rotated across the lower abdomen (avoiding the navel), or alternatively the flank/love-handle or upper thigh.

Storage & handling

Store lyophilized powder frozen (around -20 C) or refrigerated; after reconstitution refrigerate at 2-8 C, protect from light, and avoid freeze-thaw cycles. Reconstituted blend is generally used within several weeks.

Side effects

• Injection-site reactions (redness, swelling, irritation, bruising) Mild · Common
• Fatigue or lethargy Mild · Uncommon
• Headache Mild · Uncommon
• Nausea or transient GI upset Mild · Uncommon
• Flushing or transient blood-pressure/heart-rate changes Moderate · Rare
• Allergic or hypersensitivity reaction Severe · Rare

Research summary

KLOW is not a single molecule but a community-popularized blend combining four separately studied peptides, so no integrated trial of the stack itself exists; the evidence base is the sum of its parts, and it is overwhelmingly preclinical. GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is the best-characterized component, with decades of in vitro and animal data plus topical human dermatology studies showing collagen/glycosaminoglycan stimulation, wound remodeling, and broad gene-expression modulation (Pickart). BPC-157, a synthetic stable gastric pentadecapeptide, shows robust rodent results for tendon, ligament, muscle, bone, and gut healing via angiogenesis, fibroblast activity, and nitric-oxide pathway modulation, but human data are limited to a small number of pilot studies and it remains unapproved and banned in sport. TB-500 corresponds to an active region of thymosin beta-4, an actin-sequestering peptide that promotes cell migration, angiogenesis, and re-epithelialization in preclinical wound and cardiac models, with human evidence still sparse. KPV, the C-terminal tripeptide of alpha-MSH, demonstrates anti-inflammatory activity in cell and colitis models through NF-kB and MAPK inhibition without melanocortin-receptor binding. Overall the components have plausible, mechanistically complementary regenerative and anti-inflammatory rationales, but the combination lacks controlled human trials, standardized pharmacokinetics, and long-term safety data, and these peptides are generally sold for research use only rather than as approved drugs. All dosing figures below reflect community and vendor-reported research protocols, not clinical recommendations.

Key references

• https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC5498804/
• https://pubmed.ncbi.nlm.nih.gov/29986520/
• https://pubmed.ncbi.nlm.nih.gov/40756949/
• https://doi.org/10.3390/app16126202

Related compounds